TORONTO—Replikins Ltd., which tracks, studies and develops synthetic vaccines for viruses such as H1N1 and H5N1, recently reported a genomic understanding of the evolution of lethal virus gene structures in Zika and closely related Flaviviruses, which has led to the development of a trivalent vaccine for Zika, Dengue and Japanese Encephalitis. The Zika-Dengue-Japanese Encephalitis Replikins Synthetic Blocker-Vaccine candidate was designed and manufactured by Replikins and is in animal testing, with a goal of beginning human trials this July. The vaccine candidate is based on the work of Drs. Samuel and Elenore Bogoch of Boston University School of Medicine, the Foundation for Research on the Nervous System and Replikins, who found conserved Replikins gene sequences shared by the three Flaviviruses, and a suggestion of transfer of Replikins between them over time.